The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
TGF-β blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma
Open accessAbstract
Although the role of TGF-β in tumor progression has been studied extensively, its impact on drug delivery in tumors remains far from understood. In this study, we examined the effect of TGF-β blockade on the delivery and efficacy of conventional therapeutics and nanotherapeutics in orthotopic mammary carcinoma mouse models. We used both genetic (overexpression of sTβRII, a soluble TGF-β type II receptor) and pharmacologic (1D11, a TGF-β neutralizing antibody) approaches to block TGF-β signaling. In two orthotopic mammary carcinoma models (human MDA-MB-231 and murine 4T1 cell lines), TGF-β blockade significantly decreased tumor growth and metastasis. TGF-β blockade also increased the recruitment and incorporation of perivascular cells into tumor blood vessels and increased the fraction of perfused vessels. Moreover, TGF-β blockade normalized the tumor interstitial matrix by decreasing collagen I content. As a result of this vessel and interstitial matrix normalization, TGF-β blockade improved the intratumoral penetration of both a low-molecular-weight conventional chemotherapeutic drug and a nanotherapeutic agent, leading to better control of tumor growth.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“First, TGF-β blockade normalizes tumor vasculature—manifested by a reduction in vessel density, improved vessel maturity, and increased perfusion of vessels—and improves chemotherapy delivery into tumors (26).”
BackgroundSelf-citation(1989) · PubMed · Cited by 3,343
Delivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,180
Self-citationMolecular regulation of vessel maturation
Jain, R. K. (2003) · Nature Medicine · doi:10.1038/nm0603-685 · Cited by 2,529
Self-citationAccumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size
Cabral, H., Matsumoto, Y., Mizuno, K., Chen, Q., Murakami, M., Kimura, M., Terada, Y., Kano, M. R., Miyazono, K., Uesaka, M., et al. (2011) · Nature Nanotechnology · doi:10.1038/nnano.2011.166 · Cited by 2,429
Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases
Carmeliet, P., & Jain, R. K. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3455 · Cited by 1,675
Self-citationNormalization of the Vasculature for Treatment of Cancer and Other Diseases
Goel, S., Duda, D. G., Xu, L., Munn, L. L., Boucher, Y., Fukumura, D., & Jain, R. K. (2011) · Physiological Reviews · doi:10.1152/physrev.00038.2010 · Cited by 1,605
Self-citationTong, R. T., Boucher, Y., Kozin, S. V., Winkler, F., Hicklin, D. J., & Jain, R. K. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0074 · Cited by 1,189 · cited 2×
“The restored pressure gradient increases transvascular bulk fluid flow and contributes to increased penetration of drugs (22).”
BackgroundSelf-citationRole of extracellular matrix assembly in interstitial transport in solid tumors.
Netti, P. A., Berk, D. A., Swartz, M. A., Grodzinsky, A. J., & Jain, R. K. (2000) · PubMed · Cited by 1,165
Self-citationChauhan, V. P., Stylianopoulos, T., Martin, J. D., Popović, Z., Chen, O., Kamoun, W. S., Bawendi, M. G., Fukumura, D., & Jain, R. K. (2012) · Nature Nanotechnology · doi:10.1038/nnano.2012.45 · Cited by 1,101
Self-citationCauses, consequences, and remedies for growth-induced solid stress in murine and human tumors
Stylianopoulos, T., Martin, J. D., Chauhan, V. P., Jain, S. R., Diop-Frimpong, B., Bardeesy, N., Smith, B. L., Ferrone, C. R., Hornicek, F. J., Boucher, Y., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1213353109 · Cited by 943
Self-citationEndothelial-Mural Cell Signaling in Vascular Development and Angiogenesis
Gaengel, K., Genové, G., Armulik, A., & Betsholtz, C. (2009) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.161521 · Cited by 933
Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation
Brown, E., McKee, T., diTomaso, E., Pluen, A., Seed, B., Boucher, Y., & Jain, R. K. (2003) · Nature Medicine · doi:10.1038/nm879 · Cited by 836
Self-citationDelivery of molecular and cellular medicine to solid tumors
Jain, R. K. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.011 · Cited by 774
Self-citationDiop-Frimpong, B., Chauhan, V. P., Krane, S., Boucher, Y., & Jain, R. K. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018892108 · Cited by 733
Self-citationPluen, A., Boucher, Y., Ramanujan, S., McKee, T. D., Gohongi, T., di Tomaso, E., Brown, E. B., Izumi, Y., Campbell, R. B., Berk, D. A., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081626898 · Cited by 603
Self-citationDelivery of Molecular and Nanoscale Medicine to Tumors: Transport Barriers and Strategies
Chauhan, V. P., Stylianopoulos, T., Boucher, Y., & Jain, R. K. (2011) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-061010-114300 · Cited by 597
Self-citationJain, R. K. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00131-9 · Cited by 529
Self-citationTransforming growth factor-β in cancer and metastasis
Jakowlew, S. B. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-9006-2 · Cited by 517
Blockade of TGF-β inhibits mammary tumor cell viability, migration, and metastases
Muraoka, R. S., Dumont, N., Ritter, C. A., Dugger, T. C., Brantley, D. M., Chen, J., Easterly, E., Roebuck, L. R., Ryan, S., Gotwals, P. J., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215234 · Cited by 415
Kano, M. R., Bae, Y., Iwata, C., Morishita, Y., Yashiro, M., Oka, M., Fujii, T., Komuro, A., Kiyono, K., Kaminishi, M., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611660104 · Cited by 410
The next frontier of molecular medicine: Delivery of therapeutics
Jain, R. K. (1998) · Nature Medicine · doi:10.1038/nm0698-655 · Cited by 407
Self-citationMcKee, T. D., Grandi, P., Mok, W., Alexandrakis, G., Insin, N., Zimmer, J. P., Bawendi, M. G., Boucher, Y., Breakefield, X. O., & Jain, R. K. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2242 · Cited by 397
Self-citationMonsky, W. L., Fukumura, D., Gohongi, T., Ancukiewcz, M., Weich, H. A., Torchilin, V. P., Yuan, F., & Jain, R. K. (1999) · PubMed · Cited by 368
Self-citationGrantab, R., Sivananthan, S., & Tannock, I. F. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3077 · Cited by 254
Evidence that Furin Is an Authentic Transforming Growth Factor-β1-Converting Enzyme
Dubois, C. M., Blanchette, F., Laprise, M.-H., Leduc, R., Grondin, F., & Seidah, N. G. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63970-3 · Cited by 247
Sawyer, J. S., Anderson, B. D., Beight, D. W., Campbell, R. M., Jones, M. L., Herron, D. K., Lampe, J. W., McCowan, J. R., McMillen, W. T., Mort, N., et al. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0205705 · Cited by 236
Nam, J.-S., Terabe, M., Mamura, M., Kang, M.-J., Chae, H., Stuelten, C., Kohn, E., Tang, B., Sabzevari, H., Anver, M. R., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0215 · Cited by 233
TGF- Biology in Mammary Development and Breast Cancer
Moses, H., & Barcellos-Hoff, M. H. (2011) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a003277 · Cited by 230
Proprotein convertases: “Master switches” in the regulation of tumor growth and progression
Bassi, D. E., Fu, J., Lopez de Cicco, R., & Klein-Szanto, A. J. P. (2005) · Molecular Carcinogenesis · doi:10.1002/mc.20134 · Cited by 229
Evaluation of Anti-TGF-β2 Antibody as a New Postoperative Anti-scarring Agent in Glaucoma Surgery
Mead, A. L., Wong, T. T. L., Cordeiro, M. F., Anderson, I. K., & Khaw, P. T. (2003) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.02-0978 · Cited by 225
Ehata, S., Hanyu, A., Fujime, M., Katsuno, Y., Fukunaga, E., Goto, K., Ishikawa, Y., Nomura, K., Yokoo, H., Shimizu, T., et al. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2006.00357.x · Cited by 180
Throckmorton, D. C., Brogden, A. P., Min, B., Rasmussen, H., & Kashgarian, M. (1995) · Kidney International · doi:10.1038/ki.1995.274 · Cited by 174
Zhong, Z., Carroll, K. D., Policarpio, D., Osborn, C., Gregory, M., Bassi, R., Jimenez, X., Prewett, M., Liebisch, G., Persaud, K., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1634 · Cited by 123
TGF Beta Inhibition for Cancer Therapy
Saunier, E. F., & Akhurst, R. J. (2006) · Current Cancer Drug Targets · doi:10.2174/156800906778742460 · Cited by 114
Stromal regulation of vessel stability by MMP14 and TGFβ
Sounni, N. E., Dehne, K., van Kempen, L. C. L. T., Egeblad, M., Affara, N. I., Cuevas, I., Wiesen, J. F., Junankar, S. R., Korets, L. V., Lee, J., et al. (2010) · Disease Models & Mechanisms · doi:10.1242/dmm.003863 · Cited by 106
Choi, J., Credit, K., Henderson, K., Deverkadra, R., He, Z., Wiig, H., Vanpelt, H. M., & Flessner, M. F. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2141 · Cited by 105
Increased Furin Activity Enhances the Malignant Phenotype of Human Head and Neck Cancer Cells
Bassi, D., Mahloogi, H., de Cicco, R. L., & Klein–Szanto, A. J. (2003) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63838-2 · Cited by 102
Jang, S. H., Wientjes, M. G., & Au, J. L. ‐. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38848-2 · Cited by 100
Leitlein, J., Aulwurm, S., Waltereit, R., Naumann, U., Wagenknecht, B., Garten, W., Weller, M., & Platten, M. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.12.7238 · Cited by 98
Ehata, S., Hanyu, A., Hayashi, M., Aburatani, H., Kato, Y., Fujime, Μ., Saitoh, M., Miyazawa, K., Imamura, T., & Miyazono, K. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1522 · Cited by 96
Vilchis‐Landeros, M. M., Montiel-Hernández, J. L., Mendoza, V., Mendoza‐Hernández, G., & López‐Casillas, F. (2001) · Biochemical Journal · doi:10.1042/0264-6021:3550215 · Cited by 89
Bandyopadhyay, A. M., Zhu, Y., Malik, S. N., Kreisberg, J. I., Brattain, M. G., Sprague, E. A., Luo, J., López‐Casillas, F., & Sun, L. (2002) · Oncogene · doi:10.1038/sj.onc.1205439 · Cited by 87
Clinical aspects of drug delivery to tumors
Au, J. L. ‐., Jang, S. H., & Wientjes, M. G. (2002) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00488-6 · Cited by 85
Bandyopadhyay, A. M., Wang, L., López‐Casillas, F., Mendoza, V., Yeh, I., & Sun, L. (2004) · The Prostate · doi:10.1002/pros.20166 · Cited by 78
Wang, Y., & Yuan, F. (2006) · Annals of Biomedical Engineering · doi:10.1007/s10439-005-9007-2 · Cited by 77
Liao, S., Liu, J., Lin, P., Shi, T., Jain, R. K., & Xu, L. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2429 · Cited by 75
Self-citationSalnikov, A. V., Roswall, P., Sundberg, C., Gardner, H., Heldin, N., & Rubin, K. (2005) · Laboratory Investigation · doi:10.1038/labinvest.3700252 · Cited by 58
Yuan, F., Krol, A., & Tong, S. (2001) · Annals of Biomedical Engineering · doi:10.1114/1.1424915 · Cited by 51
Characterization of TGF-β-regulated interleukin-8 expression in human prostate cancer cells
Lu, S., & Dong, Z. (2006) · The Prostate · doi:10.1002/pros.20424 · Cited by 38
Seidah, N. G. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-382219-2.00727-4 · Cited by 28
Dentelli, P., Rosso, A., Calvi, C., Ghiringhello, B., Garbarino, G. M., Camussi, G., Pegoraro, L., & Brizzi, M. F. (2004) · Oncogene · doi:10.1038/sj.onc.1207290 · Cited by 26
Cited by
Extracellular matrix structure
Theocharis, A. D., Skandalis, S. S., Gialeli, C., & Karamanos, N. K. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.11.001 · Cited by 2,598
“Blocking TGF-β signaling can normalize both blood vessels and ECM within tumor stroma and enhance the treatment outcome of liposomal doxorubicin in experimental models [362, 363].”
BackgroundThe extracellular matrix modulates the hallmarks of cancer
Pickup, M. W., Mouw, J. K., & Weaver, V. M. (2014) · EMBO reports · doi:10.15252/embr.201439246 · Cited by 1,996
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Jain, R. K. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.006 · Cited by 1,589
Self-citationDiverse Applications of Nanomedicine
Pelaz, B., Alexiou, C., Alvarez-Puebla, R. A., Alves, F., Andrews, A. M., Ashraf, S., Balogh, L. P., Ballerini, L., Bestetti, A., Brendel, C., et al. (2017) · ACS Nano · doi:10.1021/acsnano.6b06040 · Cited by 1,350
Normalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
Jain, R. K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.3653 · Cited by 1,248
Self-citation
Metadata
- Authors
- Liu, J., Liao, S., Diop-Frimpong, B., Chen, W., Goel, S., Naxerova, K., Ancukiewicz, M., Boucher, Y., Jain, R. K., & Xu, L.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2012-09-20
- Volume
- 109
- Issue
- 41
- Pages
- 16618-16623
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2075629192
- Cited by
- 330
- References
- 52
- FWCI
- 6.62
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.